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Abstract 21 
Airway epithelium is the primary target of many respiratory viruses. However, virus induction and 22 
antagonism of host responses by human airway epithelium remains poorly understood. To address 23 
this, we developed a model of respiratory syncytial virus (RSV) infection based on well- 24 
differentiated pediatric primary bronchial epithelial cell cultures (WD-PBECs) that mimics 25 
hallmarks of RSV disease in infants. RSV is the most important respiratory viral pathogen in young 26 
infants worldwide. We found that RSV induces a potent antiviral state in WD-PBECs that was 27 
mediated in part by secreted factors, including interferon lambda-1 (IFNλ1)/IL-29. In contrast, type 28 
I interferons were not detected following RSV infection of WD-PBECs., Interferon (IFN) 29 
responses in RSV-infected WD-PBECs reflected those in lower airway samples from RSV-30 
hospitalized infants. In view of the prominence of IL-29, we determined whether recombinant IL-31 
29 treatment of WD-PBECs before or after infection abrogated RSV replication.  Interestingly, IL-32 
29 demonstrated prophylactic, but not therapeutic, potential against RSV. The absence of 33 
therapeutic potential reflected effective RSV antagonism of IFN-mediated antiviral responses in 34 
infected cells. Our data are consistent with RSV non-structural proteins 1 and/or 2 perturbing the 35 
Jak-STAT signaling pathway, with concomitant reduced expression of antiviral effector molecules, 36 
such as MxA/B. Antagonism of Jak-STAT signaling was restricted to RSV-infected cells in WD-37 
PBEC cultures. Importantly, our study provides the rationale to further explore IL-29 as a novel 38 
RSV prophylactic. 39 
Importance 40 
Most respiratory viruses target airway epithelium for infection and replication, which is central to 41 
causing disease. However, for most human viruses we have a poor understanding of their 42 
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interactions with human airway epithelium. Respiratory syncytial virus (RSV) is the most 43 
important viral pathogen of young infants. To help understand RSV interactions with pediatric 44 
airway epithelium, we previously developed 3-D primary cell cultures from infant bronchial 45 
epithelium that reproduce several hallmarks of RSV infection in infants, indicating that they 46 
represent authentic surrogates of RSV infection in infants. We found that RSV induced a potent 47 
antiviral state in these cultures and that type III interferon (IL-29) was involved. Indeed, our data 48 
suggest that IL-29 has potential to prevent RSV disease. However, we also demonstrated that RSV 49 
efficiently circumvents this antiviral immune response and identified mechanisms by which this 50 
may occur. Our study provides new insights into RSV interaction with pediatric airway epithelium. 51 
52 
Introduction 53 
Airway epithelium is an extremely important barrier to respiratory pathogens. It is also the primary 54 
infection target for many respiratory viruses. Elucidating the interactions between respiratory 55 
viruses and airway epithelium is fundamental to understanding aspects of their pathogenesis. We 56 
recently developed and characterized models of respiratory syncytial virus (RSV) infection based 57 
on well-differentiated pediatric primary airway epithelial cells derived from pediatric bronchial 58 
(WD-PBECs) or nasal (WD-PNECs) brushings (1, 2). RSV is the primary viral cause of infant 59 
hospitalizations in the first year of life and is capable of repeated infections throughout life (3). 60 
Despite its original isolation in 1957 (4), no effective RSV therapies or vaccines are available. The 61 
mechanisms by which RSV causes disease and is capable of repeated infections in humans remain 62 
an enigma. Our models reproduce several hallmarks of RSV infection in vivo, suggesting that they 63 
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provide authentic surrogates with which to study RSV-induced innate immune responses and 64 
interaction with human airway epithelium (1, 2).  65 
We previously reported secretion of high levels of CXCL10, an interferon-stimulated gene (ISG) 66 
product, from RSV-infected WD-PBECs (1, 2). This is consistent with the induction of an 67 
interferon (IFN)-mediated antiviral response to infection. IFNs are a heterogeneous family of 68 
cytokines with well characterized capacities to induce antiviral states in cells (5–7). They include 69 
types I (IFN-α/β), II (IFNγ) and III (IFNλs), only the first and last of which are expressed by airway 70 
epithelial cells upon appropriate stimulation (8–10). Despite considerable CXCL10 secretion, we 71 
detected no IFN-α/β secretion from RSV-infected WD-PBECs, while little or no IFN-α/β was 72 
detected in nasal or bronchoalveolar lavages from RSV-infected infants (1, 2, 11–13). In contrast, 73 
little is known about IFNλs responses to RSV infection of airway epithelium in vitro and especially 74 
in vivo. IFNλs comprise three closely related molecules designated IFNλ1 (IL-29), IFNλ2 (IL-28A) 75 
and IFNλ3 (IL-28B) (IFNλ2 and 3 share 96% identity) (14). They are induced by viruses, such as 76 
influenza A virus and rhinovirus, and inhibit replication of HCV and HIV. Interestingly, we and 77 
others recently demonstrated that IFNλs, rather than IFN-α/β, were induced following RSV 78 
infection of primary monolayer or well-differentiated nasal and bronchial epithelial cell cultures 79 
(2, 15). This suggested a role for IFNλs in RSV-induced antiviral responses. IFNλs induce antiviral 80 
states by signaling through a heterodimeric receptor complex composed of IL-28Rα and IL-10RA 81 
(14). This activates signal transduction through the Jak/STAT pathway in a manner that is virtually 82 
identical to IFN-α/β, resulting in phosphorylation of mainly signal transducer and activator of 83 
transcription (STAT)1 (pSTAT1) and STAT2 (pSTAT2) and, to a lesser extent, STAT3, 4 and 5. 84 
This is followed by pSTAT homo- or heterodimerisation, complexing with interferon regulatory 85 
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factor 9 (IRF9), nuclear translocation and induction of numerous ISGs, such as CXCL10 or the 86 
potent antiviral protein MxA (14, 16–18). 87 
In the current study, we explored the induction of antiviral responses following RSV infection of 88 
WD-PBECs. We found that RSV induced a potent antiviral state against the related Sendai virus 89 
(SeV), which was mediated, in part at least, by secreted factors including IFNλ1/IL-29. We also 90 
demonstrated that RSV-induced IL-29 secretion from WD-PBECs reflected IL-29 secretions in 91 
lower airway samples from RSV-infected infants. These RSV-induced secreted factors also 92 
demonstrated prophylactic antiviral activity against RSV, albeit with lower potency than against 93 
SeV. Pre-treatment of WD-PBEC cultures with a high dose of IL-29 reduced RSV replication, 94 
suggesting the prophylactic potential of IL-29. Interestingly, RSV non-structural proteins NS1 and 95 
NS2, which we and others have previously shown to antagonize IFN-α/β-mediated antiviral 96 
responses (19–21), were critical for RSV growth in WD-PBECs and antagonism of IL-29-induced 97 
antiviral responses. We also found that in WD-PBECs, RSV-infected cells had significantly 98 
reduced MxA/B and pSTAT2 expression levels compared to surrounding non-infected cells, 99 
indicating active antagonism of antiviral responses by RSV but restriction of this antagonism to 100 
infected cells. In summary, our data provide novel insights into the induction and antagonism of 101 
antiviral responses, and in particular IL-29, following RSV infection of human airway epithelium. 102 
 103 
Material and Methods. 104 
Cell lines and viruses. HEp-2 and Vero cell lines were cultured as previously described (22). The 105 
origin and characterization of the clinical isolate RSV BT2a were previously described (23). 106 
Recombinant RSV expressing eGFP (rA2-eGFP) was generated by cloning a cassette consisting of 107 
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the eGFP ORF-NS1 gene end signal-NS1 gene start signal into an antigenomic cDNA (D53) of 108 
RSV at the position of the NS1 ATG.  This scheme inserts an additional transcription unit encoding 109 
eGFP at the first position in the genome, preserving the RSV sequence from the leader through the 110 
NS1 5’ UTR. The eGFP containing D53 was then used to recover recombinant RSV in BSR-T7 111 
cells as described (20, 24, 25). Production of recombinant RSV expressing eGFP in place of NS1 112 
and NS2 (rA2-∆NS1/2-eGFP) has been described (26).  rA2-eGFP and rA2-∆NS1/2-eGFP stock 113 
production and titrations were performed in Vero cells. Virus stocks were harvested and stored as 114 
previously described (27). Rescue, characterization, stock production and titration of rSeV/eGFP 115 
were previously described (22). 116 
WD-PBEC culture and infection. WD-PBEC culture was described previously (28). Briefly, 117 
primary pediatric bronchial epithelial cells were obtained by bronchial brushings from healthy 118 
children undergoing elective surgery, expanded in culture flasks and seeded onto collagen-coated 119 
Transwell inserts (6.5 mm diameter, 0.4 µm pore size). Once confluence was reached, apical 120 
medium was removed to create an air-liquid interface (ALI) and trigger differentiation into pseudo-121 
stratified mucociliary epithelium. Cultures were infected 3 to 4 weeks after ALI, as previously 122 
described (28), with multiplicities of infection (MOI) specified in the Figure legends. Virus stocks 123 
were diluted in DMEM where necessary. Inoculum or DMEM-only were added to the apical 124 
surface and cultures were incubated for 1.5 h at 37°C in 5% CO2 followed by 5 rinses with 500 µl 125 
DMEM. The last rinse was retained as the 2 h virus titration point. Every 24 h thereafter, apical 126 
rinses and basal medium were collected to determine virus growth kinetics and IFN responses, 127 
respectively. Infected and control cultures were monitored daily by light and UV microscopy, 128 
where appropriate (Nikon Eclipse TE-2000U). eGFP quantification in infected cultures was 129 
performed using ImageJ software (http://rsbweb.nih.gov/ij/). 130 
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Immunofluorescence, ELISA. Immunostaining of the cultures was previously described (28). 131 
Briefly, WD-PBECs were rinsed with PBS and fixed with 4% paraformaldehyde for 20 min. 132 
Cultures were washed and stored in PBS at 4°C until used. For immunofluorescence staining, 133 
cultures were permeabilized with PBS plus 0.2% Triton X-100 (v/v) for 2 h and blocked with 0.4% 134 
BSA (w/v) in PBS for 30 min. RSV-infected cells were detected using an anti-RSV F-specific 135 
mouse monoclonal antibody (MAb) (clone 133-1H conjugated with ALEXA 488, 136 
1:200,Chemicon, US). MxA/B was detected using an anti-human Mx mouse MAb (Santa-Cruz, 137 
clone C-1, 1:200). pSTAT1 and pSTAT2 were detected using mouse anti-human pSTAT1 (pY701) 138 
MAb (BD Biosciences, 1:200) and rabbit anti-human pSTAT2 (Tyr690) polyclonal antibody 139 
(Antibodies-online, Inc, GA, USA; 1:200), respectively. The mouse anti-Mx and pSTAT1 (pY701) 140 
MAbs were detected with ALEXA-568-conjugated goat anti-mouse IgG1 (Invitrogen, 1:500), 141 
while rabbit polyclonal antibodies were detected with ALEXA-568-conjugated goat anti-rabbit 142 
IgG (H+L) (Invitrogen, 1:500) polyclonal antibodies, respectively. Inserts were mounted on 143 
microscopy slides and nuclei were counterstained using DAPI mounting medium (Vectashield). 144 
Fluorescence was detected by confocal laser scanning microscopy (TCS SP5, LEICA). MX and p-145 
STAT fluorescence intensities were determined using confocal images of infected cultures in 146 
ImageJ by dividing the Raw Integrated Density by the area of each individual cell. This was done 147 
for >120 RSV-infected and non-infected cells. 148 
IL-29 (IFN-λ1), pan-IFN-α and IFN-β concentrations in WD-PBEC basal media and in clinical 149 
samples were measured using human IFN-λ1 ELISA kits (eBioscience, UK), human IFN-β ELISA 150 
kits (R&D Systems), and human pan-IFN-α ELISA kits (Mabtech, Sweden). All ELISAs were 151 
undertaken according to the manufacturers’ instructions. IL-28A (IFN-λ2) was detected using a 152 
custom Milleplex kit, according to the manufacturer’s instructions (Merck-Millipore, UK) 153 
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Super-infection, conditioned medium and IFN-λ treatment. Super-infection experiments were 154 
undertaken by infecting WD-PBECs with RSV BT2a (MOI ≈ 4) for 72 h and super-infecting them 155 
with rSeV/eGFP (MOI ≈ 0.1), as described previously for 144 h (28). Conditioned medium (CM) 156 
experiments were performed by transferring basal medium from mock- (CMCON) or RSV-infected 157 
WD-PBECs cultures incubated with (CMRSV + αIL-29) or without (CMRSV) neutralizing antibody 158 
against IL-29 (R&D systems – MAB15981 - 10 µg/mL)  at 72 hpi into the basal compartment of 159 
fresh cultures derived from the same individuals. Twenty four hours later conditioned cultures were 160 
infected with rSeV/eGFP. To assess anti-viral effects of IFN-λ1/IL-29 against RSV, rSeV/eGFP, 161 
rA2-eGFP and rA2-ΔNS1/2-eGFP, fresh WD-PBECs or Vero cells were treated before or after 162 
infection with IFN-λ1/IL-29 (Peprotech, UK). Antiviral effects were determined by measuring 163 
eGFP fluorescence and/or virus growth kinetics.  164 
Lower airway sampling.  Samples were obtained from 10 infants (mean age 0.31 years, range 165 
0.06 -1.3 years) with severe RSV disease who were treated in the pediatric intensive care unit of 166 
the Royal Belfast Hospital for Sick Children. Samples were direct tracheobronchial aspirates or 167 
deeper suction samples following the instillation of 2 mL saline. All sampling was clinically 168 
indicated and not performed for research purposes. Fourteen uninfected and otherwise healthy 169 
children (mean age 1.7 years, range 1-2.4 years) acted as controls with blind non-bronchoscopic 170 
bronchoalveolar lavage samples obtained (after instillation of 10 mL saline) at the time of 171 
intubation for an elective surgical procedure (29). All RSV-infected infants were confirmed as 172 
having mono-infections using a multiplex virus reverse transcriptase (RT)-PCR strip for 12 173 
respiratory viruses, as previously described (30). 174 
Statistical analyses. Data obtained in vitro were described as mean [± SEM] and skewed data were 175 
log transformed before comparisons were made by Student’s paired t-test or by comparing the areas 176 
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under the curves using GraphpadPrism® 5.0. Data from RSV-infected and control children were 177 
compared using a Mann-Whitney t-test using GraphpadPrism® 5.0. p < 0.05 was considered 178 
statistically significant. 179 
Ethics. This study was approved by The Office for Research Ethics Committees Northern Ireland 180 
(ORECNI). Written informed parental consent was obtained. 181 
 182 
Results 183 
RSV infection induces an antiviral state in WD-PBECs. 184 
RSV infection of WD-PBECs generally occurred in non-contiguous or small clusters of ciliated 185 
epithelial cells (1, 2). This suggested the possibility that infection induced an anti-viral state in 186 
neighboring non-infected cells that limited viral spread. To detect the induction of antiviral 187 
responses we used rSeV/eGFP, as SeV replicates efficiently in WD-PBECs but is restricted in 188 
human cells pre-treated with human IFN (22, 28, 31). WD-PBECs (n=3 donors) were mock-189 
infected or infected with RSV BT2a (MOI~4). Seventy-two h later, the cultures were super-infected 190 
with rSeV/eGFP (MOI~0.1). Fluorescence was monitored and apical washes were collected for 191 
virus titration every 24 h post-infection (hpi) with rSeV/eGFP for 144 h. Pre-infection with RSV 192 
potently inhibited rSeV/eGFP replication, as evidenced by greatly diminished eGFP expression 193 
and rSeV/eGFP growth kinetics (Fig. 1A-C). Thus, RSV infection induced a strong antiviral state 194 
in WD-PBECs. 195 
IFNλ1/IL-29 is the predominant interferon following RSV infection in-vivo and in-vitro. 196 
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Previous work from us and others reported little or no IFN-α/β secretion following RSV infection 197 
of infants or airway epithelial cells in vitro (1, 32). In contrast, IL-29 was evident following RSV 198 
infection of primary airway (nasal) epithelial cells in vitro (2, 15). To confirm and extend these 199 
findings, we determined IFN-α/β, IL-28A and IL-29 concentrations in lower airway samples from 200 
infants hospitalized with severe RSV (n=8-10) and uninfected controls (n=11-14). Apart from one 201 
RSV-infected individual with low levels of IFNα, no IFN-α/β was detected in lower airway samples 202 
from infected infants (Fig. 2A and B). In contrast, IL-29  was significantly elevated in lower airway 203 
samples from RSV-infected patients compared to controls (Fig. 2C), although IL-28A was not (Fig. 204 
2D). Furthermore, IL-29 concentrations in basolateral medium from RSV-infected WD-PBECs 205 
were significantly increased compared to controls and were similar to those in lower airway 206 
samples (Fig. 2E). Thus , our RSV/WD-PBEC model reproduced IL-29 responses to RSV infection 207 
in-vivo. Similarly, CMRSV from 2/5 RSV-infected WD-PBECs had only low levels of IL-28A at 208 
96 hpi (Fig. 2F). The cumulative data suggest that IL-29 is an important IFN protagonist induced 209 
by RSV infection of infants and WD-PBECs and consequently might be responsible for the RSV-210 
induced antiviral responses. Whether IFN-α/β are implicated in these antiviral responses, in 211 
contrast, is unlikely, although this remains to be definitively confirmed. 212 
Secreted factors, including IL-29, are implicated in the RSV-induced antiviral state. 213 
To determine if secreted factors, including IL-29, were implicated in the antiviral state induced in 214 
RSV-infected WD-PBECS, cultures (n=2-3 donors) were mock-infected or infected with RSV 215 
BT2a (MOI~1 or 4). At 72 hpi, CMRSV (with or without anti-IL-29 – 10 µg/mL) and CMCON were 216 
transferred to uninfected cultures derived from the same individuals. The cultures were infected 24 217 
h later with rSeV/eGFP (MOI~0.1). eGFP expression (Fig. 3A, B) and rSeV/eGFP growth kinetics 218 
(Fig. 3C) indicated that factors secreted from RSV BT2a-infected WD-PBECs were responsible, 219 
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in part, for the RSV-induced antiviral effects. Importantly, when CMRSV was pre-incubated with 220 
anti-IL-29 (CMRSV + αIL-29), the ability of CMRSV to abrogate rSeV/eGFP infection was 221 
significantly reduced, suggesting an important role for IL-29 in the antiviral effect of CMRSV. 222 
IL-29 attenuates rSeV/eGFP replication in WD-PBECs. 223 
To confirm that IL-29 has antiviral activities in airway epithelium, WD-PBECs (n=2-3 donors) 224 
were pre-treated for 24 h with 100 or 1000 pg/mL IL-29 before infecting with rSeV/eGFP 225 
(MOI~0.1). These concentrations represented high physiological and super-physiological 226 
concentrations of IL-29, respectively, relative to IL-29 concentrations evident in CMRSV and lower 227 
airway samples. IL-29 demonstrated a dose-dependent suppression of eGFP expression following 228 
rSeV/eGFP infection, although both doses resulted in substantial reductions in eGFP expression 229 
relative to controls (Fig. 4A, B). Furthermore, rSeV/eGFP growth kinetics were significantly 230 
reduced following pre-treatment with both IL-29 doses (Fig. 4C), although these reductions, even 231 
at the higher dose, were lower than those evident after CMRSV pre-treatment (Fig. 3C). The data 232 
demonstrated that IL-29 has antiviral activities in airway epithelium and may account for some, 233 
but not all, of the antiviral activity associated with CMRSV. 234 
CMRSV and IL-29 prophylaxis attenuates RSV growth in WD-PBECs. 235 
To assess CMRSV antiviral activity against RSV, WD-PBECs cultures (n=2 donors) were mock-236 
infected or infected with RSV BT2a (MOI~4). At 72 hpi, CMCON and CMRSV were transferred to 237 
uninfected cultures derived from the same individuals. CM-treated cultures were infected with rA2-238 
eGFP (MOI~0.1) 24 h later and fluorescence was monitored for 96 h (Fig. 5A). The eGFP 239 
expression data demonstrated a similar, albeit lower, antiviral effect of CMRSV against RSV 240 
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compared with rSeV/eGFP (Fig. 5A). This was also reflected in significantly reduced rA2-eGFP 241 
growth kinetics in CMRSV-treated compared to CMCON-treated WD-PBEC cultures (Fig. 5B).  242 
To assess whether IL-29 had prophylactic or therapeutic potential against the clinical isolate RSV 243 
BT2a, cultures (n=3 donors) were untreated or treated with IL-29 for 24 h before infection 244 
(MOI~0.01) (1 ng/mL or 100 ng/mL), or at 2 or 24 hpi (100 ng/mL). Pre-treatment with 100 ng/mL 245 
IL-29 significantly reduced RSV replication (p<0.05), while pre-treatment with 1 ng/mL IL-29 did 246 
not (Fig. 5C). In contrast, IL-29 did not demonstrate therapeutic potential against RSV under our 247 
experimental conditions (Fig. 5D). The cumulative data from Figs. 3 nad 5 suggested that RSV is 248 
more resistant to CMRSV and IL-29 than rSeV/eGFP, and that the antiviral activity of CMRSV 249 
against RSV in WD-PBECs is similar to that evident following pre-treatment with 100 ng/mL IL-250 
29. In view of the considerably lower levels of IL-29 evident in CMRSV than those used in these 251 
experiments, IL-29 is unlikely to be solely responsible for the limited spread of RSV in WD-252 
PBECs. 253 
RSV NS proteins antagonize IL-29-mediated anti-viral effects. 254 
The relative resistance of RSV to IL-29 suggested efficient antagonism of the IFNλ-signaling 255 
pathway in WD-PBECs. We and others have shown that RSV NS1 and particularly NS2 are 256 
responsible for antagonizing IFN-α/β signaling through degradation of pSTAT2 (19, 33). However, 257 
the capacity of RSV NS1/2 to antagonize IFNλ-mediated innate immune responses is unknown. 258 
To determine whether these proteins were implicated in antagonising IL-29-induced responses in 259 
WD-PBECs, cultures were initially infected with recombinant RSV expressing eGFP, either wild-260 
type (rA2-eGFP) or lacking NS1 and NS2 (rA2-ΔNS1/2-eGFP) (MOI~0.1). While rA2-eGFP grew 261 
efficiently in WD-PBECs, replication of the NS1/2-deleted mutant was virtually abrogated (Fig. 262 
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6), indicating that NS1 and/or NS2 were critical for RSV replication in WD-PBECs. This result 263 
precluded the use of WD-PBECs to address antagonism of IL-29-mediated antiviral responses by 264 
RSV. As both the mutant and wild type viruses grew efficiently in Vero cells and these cells were 265 
sensitive to IFNλs stimulation (34, 35), we addressed the role of RSV NS1/2 in IL-29 antagonism 266 
in Vero cells. The cells were pre-treated with IL-29 (1 or 100 ng/ml) or mock-treated for 24 h 267 
before infection with either rA2-eGFP or rA2-ΔNS1/2-EGFP (MOI~0.1). Treated and control 268 
cultures were subsequently incubated for 72 h in the presence and absence of IL-29, respectively. 269 
Pre-treatment with 1 ng/mL IL-29 had no effect on rA2-eGFP replication, as indicated by eGFP 270 
expression kinetics, while 100 ng/mL did (Fig. 7A, C). By comparison, pre-treatment with either 271 
dose of IL-29 had much more dramatic effects on rA2-ΔNS1/2-eGFP replication than rA2-eGFP 272 
(Fig. 7B, D). Thus, RSV NS1/2 proteins are implicated in antagonizing IL-29-mediated antiviral 273 
responses. 274 
RSV antagonizes pSTAT2 and MxA/B expression in WD-PBECs. 275 
To gain insight into the mechanisms behind RSV antagonism of the antiviral responses induced in 276 
WD-PBECs, we looked at the capacity of RSV to antagonize Jak/STAT signalling and MxA/B 277 
expression on a single cell basis within individual infected and surrounding non-infected cells. As 278 
MxA/B expression is a reliable marker of IFN bioactivity (36) , we initially confirmed that RSV 279 
infection, IL-29 treatment, or CMRSV treatment induced MxA/B expression in WD-PBECs (Fig. 280 
8A and B). Furthermore, when CMRSV was pre-treated with anti-IL-29, MxA/B expression was 281 
virtually abrogated, demonstrating that MxA/B induction following CMRSV-treatment was in large 282 
part mediated by IL-29 (Fig. 8B and C). We and others previously reported that RSV NS proteins 283 
block the IFNα/β-stimulated Jak/STAT signalling pathway by targeting pSTAT2 for proteasomal 284 
degradation (19, 37). To study RSV antagonism of Jak/STAT signalling and MxA/B expression in 285 
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WD-PBECs, cultures (n=3-4 donors) were infected with RSV (MOI~0.1), subjected to daily apical 286 
rinses and basolateral medium change, fixed, permeabilized and co-stained for RSV F and either 287 
pSTAT1, pSTAT2 or MxA/B at 144 hpi (Fig. 9A-F). pSTAT1 fluorescence intensities were similar 288 
in both infected and non-infected cells (Fig. 9E, F). In contrast, pSTAT2 protein was significantly 289 
diminished (Fig. 9C, D), while MxA/B proteins were virtually absent (Fig. 9A, B), in RSV-infected 290 
compared to surrounding non-infected cells. Thus, antagonism of the RSV-induced IFN-mediated 291 
antiviral responses was restricted to infected cells and implicated the perturbation of the Jak/STAT 292 
signalling pathway by pSTAT2 down-regulation. 293 
Discussion 294 
Innate immune responses are critical first lines of defense against virus infection (38, 39). The 295 
capacity for viruses to antagonize or circumvent these responses is essential for their successful 296 
replication. Our RSV/WD-PBEC model provided a unique opportunity to study the induction and 297 
antagonism of innate antiviral immune responses by RSV in a morphologically- and 298 
physiologically-authentic model of pediatric bronchial epithelium. We exploited the fact that RSV 299 
infection does not lead to gross destruction of WD-PBECs to establish super-infection experiments 300 
with rSeV/eGFP. rSeV/eGFP was particularly useful for these experiments as it replicates very 301 
efficiently in untreated WD-PBECs but is sensitive to human IFN (28, 31). These characteristics 302 
provided the unique opportunity to establish a novel bioassay to study RSV-induced antiviral 303 
responses in WD-PBECs based on SeV-derived eGFP expression and SeV growth kinetics. 304 
Our rSeV/eGFP super-infection bioassay unambiguously demonstrated that RSV induced a potent 305 
antiviral response in WD-PBECs and that basolaterally-secreted factors were, in part, responsible 306 
for this anti-viral activity. Importantly, IFN-λs, particularly IL-29, but not IFN-α/β, were detected 307 
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in RSV-infected WD-PBECs. This is consistent with Okabayashi et al (2011), who showed a 308 
predominance of IL-29 secretion from RSV-infected primary and immortalized nasal epithelial cell 309 
monolayers (15). A major finding of our study is the preponderance of IL-29 and the absence of 310 
detectable IFN-α/β in lower airway samples from RSV-infected infants, suggesting that IFN-λs, 311 
and in particular IL-29, are the principal interferons responding to RSV infection in vitro and in 312 
vivo. The lack of detectable IFN-α/β in CMRSV, as reported previously (1), and in lower airway 313 
samples from infants hospitalized with RSV, as reported here, is consistent with earlier clinical 314 
observations (11–13). It is unclear whether this lack of detectable IFN-α/β in CMRSV is due to a 315 
failure to stimulate these responses and/or active antagonism of induction by RSV NS1/2. Indeed, 316 
using immortalized cell lines, RSV NS proteins were shown to antagonize IFNα/β induction by 317 
interacting with RIG-I, disrupting association of IRF-3 with CBP and, thereby, IRF-3 binding to 318 
the IFN-β promoter, and suppressing activation and nuclear translocation of IRF-3 (19, 40, 41) 319 
They also antagonized IFNα/β signaling by inducing proteasome-mediated degradation of pSTAT2 320 
(19, 37) . Additionally, RSV NS1, and to a lesser extent NS2, were shown to decrease cellular 321 
levels of TRAF3 and IKKɛ, both key members of the IFN response pathway (42). However, Killip 322 
et al recently demonstrated that even when viral IFNα/β antagonists were deleted, the 323 
paramyxovirus PIV5 failed to activate the IFNβ promoter, suggesting that members of the 324 
Paramyxoviridae are very inefficient at inducing IFN-α/β responses (43). The corollary, however, 325 
is that the IFN antagonistic capacities of these viruses likely evolved to cope with IFN-λs, rather 326 
than IFN-α/β, responses. 327 
Therefore, we evaluated the capacity of RSV NS1/2 to antagonize IFN-λ1/IL-29-mediated antiviral 328 
effects. We demonstrated that NS1 and/or NS2 were essential for RSV resistance to IL-29-329 
mediated antiviral activity in Vero cells and for replication of RSV in WD-PBECs. At a cellular 330 
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level in WD-PBECs, we showed that RSV infection inhibited the interferon-inducible Jak/STAT 331 
pathway through p-STAT2 suppression, with concomitant reduction of the expression of the IFN-332 
induced antiviral GTPases, MxA/B (18). However, this inhibition in WD-PBECs was restricted to 333 
infected cells. As MxA/B are reliable markers of IFN bioactivity and IL-29 was the only IFN 334 
detected in CMRSV, our cumulative data are consistent with a model in which RSV infection 335 
induces IL-29-mediated antiviral activity in WD-PBECs but that RSV NS1/2 proteins efficiently 336 
antagonize these responses only in infected cells through pSTAT2 degradation. Although IFNα/β 337 
were not detected in our assays, the possibility remains that very low biologically active levels 338 
were present. Further work is therefore needed to definitively exclude their role in RSV-induced 339 
antiviral responses in WD-PBECs. 340 
There is an increasing body of evidence confirming the capacity of IL-29 to induce antiviral states 341 
in infected cells (5, 8, 44). Our data extend this IL-29 capacity to SeV and RSV. We found no 342 
evidence that IL-29 has therapeutic potential against RSV infection. However, we present evidence 343 
that IL-29 has prophylactic potential against RSV, as demonstrated by retarded RSV growth 344 
kinetics in IL-29 pre-treated WD-PBECs compared with untreated controls. These data provide the 345 
rationale for further studies on IL-29 prophylaxis to modulate RSV pathogenesis. This is of 346 
particular interest for individuals at risk for severe illness due to RSV infection, although more 347 
work is needed to better understand IL-29 responses in vivo. Moreover, the IL-29-mediated 348 
antiviral effects against RSV, combined with the tissue-restriction of the type III IFN receptor to 349 
epithelial cells, the liver and some leukocytes suggest that IL-29 prophylaxis may result in limited 350 
toxicities that are typical of type I IFN therapy (45). Indeed, early data from clinical trials using 351 
IFN-λ to treat chronic hepatitis C virus support this possibility (46). 352 
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Our evidence suggests the exciting prospect of potentially novel potent antiviral molecules in 353 
CMRSV that are not explained by its IL-29 content alone. Neutralizing IL-29 eliminated a large 354 
portion of the antiviral activity of CMRSV. However, CMRSV demonstrated greater antiviral potency 355 
than 1 ng/mL recombinant IL-29, which represents ~25 fold increase relative to the mean IL-29 356 
concentration in CMRSV.  Therefore, it is possible that other molecules in CMRSV act in synergy 357 
with IL-29 to exert its impressive antiviral activities. Indeed, such synergistic antiviral activity was 358 
previously reported for IFNα/β and INFγ against herpes simplex virus 1 (HSV-1), hepatitis C virus 359 
(HCV) and severe acute respiratory syndrome-associated coronavirus (SARS-CoV)(47–49). 360 
However, further work is required to identify such molecules and determine whether such synergy 361 
is evident in our WD-PBEC model. 362 
Finally, there is increasing molecular diagnostic evidence demonstrating concomitant dual or 363 
multiple respiratory viral infections in individuals (50, 51). Debate is ongoing as to whether such 364 
dual/multi-infections result in exacerbated disease compared with mono-infections. Extrapolation 365 
of our data to the clinic suggests that a primary infection with RSV would result in the induction 366 
of an antiviral state in the airway epithelium that may greatly compromise the capacity of 367 
subsequent viruses to infect and replicate, unless the second virus was adept at circumventing the 368 
pre-established innate immune responses. This is consistent with a recent study showing that 369 
infection with multiple respiratory viruses correlated with less severe disease (52). 370 
In conclusion, our study significantly advances our understanding of RSV induction and 371 
antagonism of type III IFN responses in human airway epithelium. Importantly, it provides the 372 
rationale for dissecting the molecular mechanisms by which these occur and the possible 373 
exploitation of IL-29 as a novel RSV prophylactic, either alone or in combination with other yet-374 
to-be discovered CMRSV antiviral molecules. 375 
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Figure Legends. 547 
Figure 1. Pre-infection of WD-PBECs with RSV induces an anti-viral effect. WD-PBECs (n = 548 
3 donors) were mock-infected or infected with RSV BT2a (MOI~4). Seventy two hpi, RSV- and 549 
mock-infected cultures were super-infected with rSeV/eGFP (MOI~0.1). (A) RSV-infected and 550 
mock-infected cultures were monitored by UV microscopy every 24 h (original magnification, x4). 551 
These photos are representative of duplicate cultures from 3 individual donors. (B) eGFP 552 
expression was quantified every 24 h by measuring the % of green pixels in 3 different microscope 553 
fields. (C) Virus growth kinetics was determined by titrating rSeV/eGFP in apical washes at 24 h 554 
intervals following infection. Data are presented as mean ± SEM log10 fluorescent focus units 555 
(ffu)/mL. 556 
Figure 2. Type III IFN, but not type I IFN, is detected following RSV infection in-vivo and in-557 
vitro. Lower airway samples from infants hospitalized for severe RSV infection (n=10 donors) and 558 
healthy controls (n=14 donors) were analyzed for pan-IFN-α (A), IFN-β (B), IL-29 (C) or IL-28A 559 
(D) by ELISA. Data are presented as mean ± SEM. Statistical analyses were undertaken using a 560 
non-parametric t-test followed by a Mann-Whitney test. ***p = 0.0005. WD-PBECs (n=5 donors) 561 
were infected with RSV (MOI~4). IL-29 (E) or IL-28A (F) secretions in the basolateral medium 562 
of RSV- and mock-infected cultures harvested at 24 and 96 hpi were measured. As the medium 563 
was replaced every day, the data correspond to IFN secretions within the preceding 24 h. Values 564 
are means ± SEM. **p<0.01. 565 
Figure 3. RSV-induced antiviral effect is partially mediated by IL-29. WD-PBECs (n=2-4 566 
donors) were infected with RSV BT2a (MOI~4) or mock infected. Seventy two hpi, the basal 567 
medium of mock- (CMCON) or RSV-infected cultures incubated with (CMRSV + αIL-29) or without 568 
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(CMRSV) neutralizing antibody against IL-29 (10 µg/mL) was transferred into the basal 569 
compartment of fresh cultures from the same individual donor. Twenty four h later, the cultures 570 
were infected with rSeV/eGFP (MOI~0.1). (A) eGFP expression in CMCON-, CMRSV + αIL-29- 571 
and CMRSV-treated rSeV/eGFP-infected WD-PBECs over time (original magnification x4). (B) 572 
eGFP expression was quantified every 24 h by measuring the % green pixels in 5 random 573 
microscopic fields. (C) Virus growth kinetics were determined by titrating rSeV/eGFP in apical 574 
washes at 24 h intervals following infection. Data are presented as mean ± SEM log10 ffu/mL. Area 575 
under the curves were calculated and compared using an unpaired Student’s t-test. **p < 0.01; ***p 576 
< 0.001. 577 
Figure 4. Influence of IL-29 pre-treatment on rSeV/eGFP growth in WD-PBECs. WD-PBECs 578 
(n=3 donors) were pre-treated with IL-29 (100 pg/mL and 1000 pg/mL) or mock-treated. Twenty 579 
four h later, cultures were infected with rSeV/eGFP at an MOI~0.1.  UV microphotographs were 580 
taken every 24 hpi (A). Original magnification, x4.  eGFP expression was quantified every 24 hpi 581 
by measuring the % green pixels in 3 random microscopic fields (B). Virus growth kinetics were 582 
determined by titrating rSeV/eGFP in apical washes at 24 h intervals following infection (C). Data 583 
are presented as mean ± SEM log10 ffu/mL. Area under the curves were calculated and compared 584 
using an unpaired Student’s t-test.  *p<0.05. 585 
Figure 5. CMRSV and IL-29 pre-treatment attenuates RSV growth in WD-PBECs. WD-586 
PBECs (n=2 donors) were infected in duplicate with RSV BT2a (MOI~4) or mock infected. 587 
Seventy two hpi, the basal medium of mock- (CMCON) or RSV-infected cultures (CMRSV) was 588 
transferred into the basal compartment of fresh cultures from the same individual donor. Twenty 589 
four h later, the cultures were infected with rA2-eGFP (MOI~0.1). eGFP expression was quantified 590 
every 24 h by measuring the % green pixels in 3 different microscopic fields (A). Virus growth 591 
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kinetics were determined by titrating rA2-eGFP in apical washes at 24 h intervals following 592 
infection (B). WD-PBECs (n=2-3 donors) were pre-treated with IL-29 (1 or 100 ng/mL). Twenty 593 
four h later, cultures were infected with RSV BT2a at an MOI~0.01 (C). WD-PBECS (n=3 donors) 594 
were infected with RSV BT2a at an MOI of 0.01. Two or 24 hpi, infected cultures were treated 595 
with IL-29 (100 ng/mL) (D). Virus growth kinetics was determined by titrating RSV in apical 596 
washes every 24 h following infection for (C) and (D). Data are presented as mean + SEM log10 597 
TCID50/mL. Area under the curves were calculated and compared using an unpaired Student’s t-598 
test. *p < 0.05, **p < 0.01. 599 
Figure 6. rA2-ΔNS1/2-eGFP does not infect efficiently WD-PBECs. WD-PBEC cultures were 600 
infected in duplicate with either rA2-eGFP or rA2-ΔNS1/2-eGFP (MOI~1) for 96 h. Representative 601 
fluorescence pictures were taken at 96 hpi (A). rA2-eGFP or rA2-ΔNS1/2-eGFP titers at 96 hpi 602 
were measured (B). Data are presented as mean ± SEM log10TCID50/mL. *** p < 0.001. 603 
Figure 7. RSV NS1/2 partially counteract IL-29-mediated anti-viral effects. Vero cells were 604 
pre-treated with IL-29 (1 or 100 ng/mL) or non-treated. Twenty four h post treatment, the cells 605 
were infected with rA2-eGFP (A) or rA2-ΔNS1/2-eGFP (B) (MOI=0.1). Cultures were monitored 606 
by UV microscopy every 24 hpi (original magnification, x4). Infections were undertaken in 607 
triplicate and a surrogate for virus replication kinetics was quantified by measuring % eGFP 608 
coverage of 3-5 microscope fields at each time point (C, D). Data are presented as mean ± SEM 609 
eGFP area (% whole image) and are representative of three independent experiments in triplicate. 610 
Area under the curves were calculated and compared using an unpaired Student’s t-test. ***p < 611 
0.001.. 612 
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Figure 8. MxA/B expression is induced following RSV infection, and IL-29 or CMRSV 613 
treatment of WD-PBECs. (A) WD-PBECs were either mock-infected, RSV BT2a-infected (MOI 614 
~0.1) for 96 h, or treated with IL-29 (1 ng/mL) for 24 h. Cultures were fixed and stained for MxA/B 615 
(red) and nuclei were counter-stained with DAPI (blue). Confocal images show typical staining in 616 
WD-PBECs from 3 individual donors. (original magnification, x63). (B) and (C) MxA/B 617 
expression following treatment with CMRSV is mediated in large part by IL-29. WD-PBECs (2 618 
independent cultures from 1 donor) were incubated with either CMRSV or CMCON alone or 619 
combined with a neutralizing antibody against IL-29 (10 µg/mL) for 24 h. Cultures were fixed and 620 
stained for MxA/B and nuclei were counter-stained with DAPI. The MxA/B signal was quantified 621 
in 5 individual fields from each culture, and mean fluorescence was calculated and plotted. 622 
**p<0.01, ***p<0.001. 623 
Figure 9. RSV blocks the expression of MxA/B, p-STAT2 but not p-STAT1 in infected WD-624 
PBECs. WD-PBECs were either mock- or RSV-infected (MOI~0.1) for 96 h. Cultures were fixed 625 
and either stained for (A) MxA/B, (C) p-STAT1 or (E) p-STAT2 (red); RSV was detected using a 626 
FITC-conjugated anti-RSV-F-specific antibody (green). Confocal images show typical staining 627 
from WD-PBECs derived from 3 different individual donors (original magnification, x63). 628 
Fluorescence of MxA/B (B), p-STAT1 (D) and p-STAT2 (F) in RSV-infected and uninfected cells 629 
within RSV-infected WD-PBEC cultures was quantified by dividing the Raw Integrated Density 630 
by the Area of >120 individual cells. Fluorescence was quantified using ImageJ software. Data are 631 
presented as mean ± SEM. ***p < 0.0005. 632 
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